Speakers

• 

  Robert Ariens, (UK)

  Professor of Vascular Biology, Academic Lead of Theme Thrombosis, Leeds.
  His research focuses on fibrin clot structure and function.

• 

  S. Cataland (USA)

  Associate Professor-Clinical, Hematology, Physician, FGP-Hematology, Columbus, OH. He is a clinical/translational researcher with an emphasis on the study of patients with both aHUS and TTP.

• 

  P. Coppo (France)

  Professor of Haematology in Saint-Antoine Hospital (Paris). He leads the French reference Center for Thrombotic Microangiopathies.

• 

  S. De Meyer (Belgium)

  Associate professor at the Laboratory for Thrombosis Research, KULeuven Kulak, Kortrijk. His researches focus on the role of VWF in ischemia/reperfusion injury, gene therapy for von Willebrand disease, ADAMTS-13 and VWF biology.

• 

  Y. Dargaud (France)

  Associate Professor at the University of Lyon and a consultant hematologist, Lyon. Her special research interests include inherited bleeding disorders, hemophilia with inhibitor and bypassing therapies.

• 

  J.C.C. Eikenboom (The Netherlands)

  Professor of internal medicine, Leiden University Medical Center, Leiden. His research is focused on biology of von Willebrand factor and etiology of von Willebrand disease.

• 

  M. Galbusera (Italy)

  Head, Unit of Platelet-Endothelial Cell Interaction, IRCCS Mario Negri Institute for Pharmacological Research, Milan. Her fields of interest are related to complement, ADAMTS-13 and VWF in thrombotic microangiopathies, VWF biochemistry, platelet-endothelial cell interaction under flow condition, platelet pathophysiology in uremia.

• 

  A. Goodeve (UK)

  Department of Cardiovascular Science, University of Sheffield, Medical School, Beech Hill Road, Sheffield. She undertakes research into the molecular basis of von Willebrand disease and provides a diagnostic service for bleeding/thrombotic disorders.

• 

  A. Hill (UK)

  Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, Leeds. Honorary Senior Lecturer at the University of Leeds.  She sees more than 300 patients a year with PNH and has led in numerous developments in the management of this rare condition.

• 

  P. James (USA)

  Associate Professor, Hematologist, Dept. of Medicine, Queen’s University, Kingston, Ontario
  Hematologist and Clinician Scientist with a research program focused on inherited bleeding disorders.

• J.A. Kremer Hovinga (Switzerland)

  Head Hemostasis Research Laboratory at Berne University Hospital, Berne

• 

  B. Lämmle (Switzerland)

  Inselspital, Bern University Hospital and University of Bern,
  University Clinic of Hematology and Central Hematology Laboratory, Hemostasis Research Laboratory, Bern

• 

  F.W.G. Leebeek (The Netherlands)

  Department of Hematology, Erasmus University Medical Center, Rotterdam. He is full professor of Haematology, specialized in hemostasis and thrombosis. His research focus is on Von Willebrand factor.

• 

  Peter Lenting (France)

  Inserm U770, Le Kremlin-Bicêtre.
  His research activities are related to the biology of the factor VIII/von Willebrand complex, including the /in vivo/ analysis of mutant variants.

• 

  D. Lillicrap (Canada)

  Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen’s University, Kingston, Ontario

• 

  M. Makris (UK)

  Professor of Haemostasis and Thrombosis at University of Sheffield and Director of the Sheffield Haemophilia and Thrombosis Centre

• 

  S. Meri (Finland)

  Professor of Immunology in Helsinki. He is interested in complement-mediated diseases and microbial escape of immunity.

• 

  Federico Mingozzi (France)

  Associate Professor, University Pierre and Marie Curie, Paris, Team Leader, Genethon, Evry, France
  He’s an expert in AAV vector-mediated in vivo gene transfer and in the study of the interactions between AAV vectors and the immune system.

   

• 

  R.R. Montgomery Jr. (USA)

  Pediatric hematologist at the Blood Research Institute in Milwaukee.  He works on gene therapy of hemophilia and molecular biology of VWD.

• 

  L. Naldini (Italy)

  Director of the San Raffaele Telethon Institute for Gene Therapy and Professor at the San Raffaele University, Milan.

• 

  A.C. Nathwani (UK)

  Research Department of Haematology, Cancer Institute, Faculty of Medical Sciences, London
• 

  F. Pasinelli (Italy)

  General Manager, Fondazione Telethon, Rome

   

• 

  I. Peake (UK)

  Emeritus Professor of Molecular Medicine, Dept. of Cardiovascular Science, Univ. of Sheffield, UK.
  His research concerns the molecular genetics of VWD. He’s a collaborator in the NIH Zimmerman VWD PPG and in the 3-WINTERS Type 3 VWD European/Iranian project.

• 

  S.W. Pipe (USA)

  Prof. of Pediatrics and Pathology, Medical Director, Pediatric Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory, Univ. of Michigan, Ann Arbor, Michigan
  He is the Director of a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A.

• 

  A.M. Randi (UK)

  Faculty of Medicine, National Heart & Lung Institute, Imperial College, London

• 

  M. Roest (The Netherlands)

  Department of Clinical Chemistry and Haematology, University Medical Center Utrecht. He has developed a single step diagnostic test to measure platelet function disorders and VWF disorders in unprocessed blood.

• 

  Z. Ruggeri (USA)

  Department of Molecular and Experimental Medicine, Scripps Clinic, La Jolla, CA

• 

  J.E. Sadler (USA)

  Dept. of Medicine, Hematology Division, Dept. of Biochemistry & Molecular Biophysics, Washington University Medical School, St. Louis, MO

• 

  R. Schneppenheim (Germany)

  Medical Director and Head of the Molecular Genetic Laboratory, Dept. of Pediatric Hematology and Oncology at the Univ. Medical Center Hamburg-Eppendorf.
  His scientifin interests are related to von Willebrand disease, Structure and function of von Willebrand factor, Tumor predisposition syndromes.

• 

  P. Simioni (Italy)

  Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School. He has discovered hyperfunctional Factor IX Padua.

• 

  L. Swystun (Canada)

  Postdoctoral fellow at the Clinical and Molecular Hemostasis Research Group at Queen’s University, Kingston, Canada.
  Her work focuses on characterizing mechanisms which regulate clearance of von Willebrand factor and factor VIII.

• 

  K. Vanhoorelbeke (Belgium)

  Associate professor at KU Leuven Kulak, Laboratory for Thrombosis Research, Kortrijk.
  She deals with fundamental and translational research on ADAMTS-13, animal models for TTP and gene therapy for VWD.

• 

  D.D. Wagner (USA)

  Center for Blood Research Professor of Pediatrics, Program in Cellular and Molecular Medicine and Div. of Hematology/Oncology.
  Boston Children’s Hospital. Harvard Medical School, Boston. Vascular biologist. She found that VWF is stored in endothelium and upon release mediates platelet adhesion.

• 

  G. Young (USA)

  Director, Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles; Associate Professor of Pediatrics, University of Southern California Keck School of Medicine.
  Researches in hemophilia and pediatric thrombosis and focuses on thromboelastography research.

• 

  L. Zheng (USA)

  Associate Professor of pathology and laboratory medicine at the Univ. of Pennsylvania and Director of hematology and coagulation laboratories at the Children’s Hospital of Philadelphia.